VHL logo
BIGG Rec logo
Results: 1 - 10 of 1,823

(Screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: use of human papillomavirus (HPV) DNA genotyping) Recommendations for the general population of women. Regardless of follow-up capacity If a programme provides triage with additional tests, WHO suggests using visual inspection with acetic acid (VIA) or colposcopic impression (without histological confirmation) as the triage test rather than cytology or dual-stain cytology.

Year
2026
Institution
World Health Organization

Recommended in favor

Conditional

Recommendations for the general population of women . In settings with high follow-up capacity (60% or greater) and sufficient ablative treatment capacity, WHO suggests using HPV DNA testing with extended or limited genotyping OVER treating all HPV-positive women or triaging all HPV-positive women with additional tests. In settings with high follow-up capacity (60% or greater) and sufficient ablative treatment capacity where HPV DNA extended genotyping is used, WHO suggests: • treating all eligible women with ablative treatment who test positive for carcinogenic HPV (cHPV) types 16 (group 1a), 18 and 45 (group 1b) and 31, 33, 35, 52 and 58 (group 1c); AND triaging women who test positive for cHPV types 39, 51, 56 and 59 (group 1d); OVER • treating all eligible women with ablative treatment who test positive for cHPV types 16 (group 1a), 18 and 45 (group 1b), AND triaging women who test positive for cHPV types 31, 33, 35, 52, 58, 39, 51, 56 and 59 (groups 1c and 1d); OVER • treating all eligible women with ablative treatment who test positive for cHPV types 16 (group 1a), 18 and 45 (group 1b) AND triaging women who test positive for cHPV types 31, 33, 35, 52 and 58 (group 1c) AND returning women who test positive for cHPV types 39, 51, 56 and 59 (group 1d) to routine screening.

Year
2026
Institution
World Health Organization

Recommended in favor

Conditional

Recommendations for the general population of women . In settings with low follow-up capacity (less than 60%) and sufficient ablative treatment capacity, WHO suggests: • treating all eligible women with ablative treatment who test positive for any carcinogenic HPV (cHPV) types 16 (group 1a), 18 and 45 (group 1b), 31, 33, 35, 52 and 58 (group 1c), 39, 51, 56 and 59 (group 1d), consistent with a no-genotyping approach; • OR treating eligible women with ablative treatment who test positive for any cHPV types 16 (group 1a), 18 and 45 (group 1b) and 31, 33, 35, 52 and 58 (group 1c) [This can be done using an 8-cHPV type test (tests designed to detect the eight most cHPV types) as per WHO target product profiles for HPV screening tests, or when using extended genotyping HPV tests.] OVER • treating all eligible women with ablative treatment who test positive for cHPV types 16 (group 1a), 18 and 45 (group 1b) AND triaging women who test positive for cHPV types 31, 33, 35, 52, 58, 39, 51, 56 and 59 (groups 1c and 1d); or OVER • triaging with additional tests all women who test positive for any cHPV types (1a, 1b, 1c and 1d).

Year
2026
Institution
World Health Organization

Recommended in favor

Conditional

[Immunization to protect infants against respiratory syncytial virus disease]. For countries deciding to use a long-acting monoclonal antibody as the primary preventive strategy, WHO recommends a single dose at birth, or at the earliest opportunity thereafter if year-round administration is adopted. In a seasonal approach, administration of a single dose of a long-acting monoclonal antibody is recommended for infants and should begin shortly before the start of the RSV season, as well as at birth or the earliest opportunity thereafter for infants born during the RSV season

Year
2025
Institution
World Health Organization

Recommended

Uterine balloon tamponade is recommended for the treatment of postpartum haemorrhage due to uterine atony after vaginal birth in women who do not respond to standard first-line treatment, provided the following conditions are met:  Immediate recourse to surgical intervention and access to blood products is possible if needed.  A primary postpartum haemorrhage first-line treatment protocol (including the use of uterotonics, tranexamic acid, intravenous fluids) is available and routinely implemented.  Other causes of postpartum haemorrhage (retained placental tissue, trauma) can be reasonably excluded.  The procedure is performed by health personnel who are trained and skilled in the management of postpartum haemorrhage, including the use of uterine balloon tamponade.  Maternal condition can be regularly and adequately monitored for prompt identification of any signs of deterioration.

Year
2025
Institution
World Health Organization

Context specific recommendation

Only in specific contexts